Back to peptides

CJC-1295

aka CJC-1295 DAC, CJC-1295 no DAC, DAC:GRF, Modified GRF 1-29, Mod GRF 1-29, ModGRF(1-29), ConjuChem CJC-1295

Gh SecretagogueGh StimulationMuscle GrowthFat LossSleepIgf-1Pulsatile GhBody Composition

Last reviewed April 27, 2026 by Doserr editorial team · 9 references on this page

Information on this page is sourced from published research and is for educational purposes only. It does not constitute medical advice.

TL;DR

  • What it is: A synthetic GHRH analog sold as two chemically distinct forms: DAC (week-long half-life) and no-DAC (Mod GRF 1-29, ~30-minute half-life).
  • What it's used for: GH and IGF-1 elevation, community use focuses on fat loss, muscle growth, and sleep, body composition untested in controlled trials.
  • Evidence level:limitedLimited human PK/PD data, Phase 2 halted after a participant death.

Dose at a glance

BeginnerCommonHigher end
Per dose100 mcg (no-DAC) or 1 mg (DAC)100 mcg no-DAC (pre-bed, stacked with ipamorelin 200-300 mcg)200-300 mcg (no-DAC, multiple daily injections)
Daily total100 mcg (no-DAC once pre-bed), 1 mg/week (DAC)100 mcg (once pre-bed, no-DAC), 1-2 mg/week (DAC)200-600 mcg (no-DAC, 2-3x daily), 2 mg/week (DAC)
ScheduleOnce daily (pre-bed, no-DAC) or weekly (DAC)Once daily (no-DAC) or weekly (DAC)2-3x daily (no-DAC) or weekly (DAC)
Cycle length8 weeks8-12 weeks, 5-days-on / 2-days-off (no-DAC)12 weeks

Synthesized from community-reported ranges. Not a recommendation. Route varies by compound — see Common route in What people report below.

Half-life
With DAC: ~5.8-8.1 days estimated in humans after SC injection (PMID: 16352683), prolonged by covalent albumin binding via the DAC maleimide linker. Without DAC (Mod GRF 1-29): ~30 minutes, inferred from sermorelin pharmacology, no published human PK study exists specifically for the Mod GRF 1-29 variant.
Typical dose range
Doses below are from published research, not recommendations. DAC version (Teichman 2006, PMID: 16352683): 30, 60, 125, or 250 mcg/kg SC single dose, 30 or 60 mcg/kg weekly or biweekly in the multiple-dose arm. Ionescu 2006 (PMID: 17018654): 60 or 90 mcg/kg single SC injection. No-DAC (Mod GRF 1-29): no published controlled human dose-finding study.
Route
Subcutaneous (SC) in both published human studies (PMID: 16352683, PMID: 17018654).
Evidence tier
limited

Animal or in-vitro studies only — no published human efficacy data.

What the research shows

Each topic links to the studies behind it. Click a topic to expand.

What we don't know yet

  1. Mod GRF 1-29 (no-DAC) has essentially no direct human efficacy data, GH-stimulating activity is inferred from the DAC version and from GHRH pharmacology, not from a published controlled human trial
  2. Long-term safety of sustained GH and IGF-1 elevation from the DAC version is unstudied beyond 49 days, effects on insulin sensitivity, pituitary regulation, and glucose metabolism are uncharacterized
  3. Body composition outcomes have never been tested in a controlled human trial for either variant, the lipodystrophy Phase 2 was terminated before efficacy data were published
  4. All human clinical data come from a single company (ConjuChem) that subsequently discontinued development, no independent replication of the Teichman 2006 findings has been published
  5. The sustained GH trough elevation from the DAC version (7.5-fold increase in trough GH, PMID: 17018654) may not replicate the pulsatile pattern that drives slow-wave sleep enhancement in GHRH studies (PMID: 8772566)
  6. The cause-of-death finding from the 2006 trial halt (asymptomatic coronary artery disease) is from the attending physician's assessment as reported in news sources, not a peer-reviewed publication, independent clinical review has not been published

Run a calculation for this peptide

Reconstitution math, both directions.

Track this peptide

Log every dose, see your history, and save this protocol with one click.